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Abstract
To investigate the genomic aberrations that are
involved in lung tumorigenesis and therefore may be
developed as biomarkers for lung cancer diagnosis,
we characterized the genomic copy number changes
associated with individual genes in 14 tumors from
patients with primary non small cell lung cancer
(NSCLC). Six squamous cell carcinomas (SQCAs) and
eight adenocarcinomas (ADCAs) were examined by
high-resolution comparative genomic hybridization
(CGH) analysis of cDNA microarray. The SQCAs and
ADCAs shared common frequency distributions of
recurrent genomic gains of 63 genes and losses of
72 genes. Cluster analysis using 57 genes defined the
genomic differences between these two major histo-
logic types of NSCLC. Genomic aberrations from a
set of 18 genes showed distinct difference of primary
ADCAs from their paired normal lung tissues. The
genomic copy number of four genes was validated
by fluorescence in situ hybridization of 32 primary
NSCLC tumors, including those used for cDNA micro-
array CGH analysis; a strong correlation with cDNA
microarray CGH data emerged. The identified genomic
aberrations may be involved in the initiation and
progression of lung tumorigenesis and, most impor-
tantly, may be developed as new biomarkers for the
early detection and classification of lung cancer.
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Introduction
Lung cancer is the most common cause of cancer death
in North America. The unsatisfactory cure rate and poor
prognosis of affected patients support efforts for better
risk assessment and early detection. Non small cell lung
cancer (NSCLC), the predominant form of lung cancer, has
two major histologic subtypes: squamous cell carcinoma
(SQCA) and adenocarcinoma (ADCA) [1].
Lung tumorigenesis is a heterogeneous process that
arises after a series of clonal molecular genetic alterations,
including genomic gains and losses, particularly deletion
of tumor-suppressor genes (TSGs) and amplification of onco-
genes [2]. Therefore, defining these genomic aberrations may
help us identify tumor-specific signatures involved in the initi-
ation and progression of lung cancer and thus help produce
genomic biomarkers for the early detection of lung tumors.
Cytogenetic karyotypes have shown that NSCLCs display mul-
tiple numeric and structural chromosomal alterations [3]. Loss
of heterozygosity (LOH) analysis further disclosed major dif-
ferences in patterns of allelic imbalances between ADCA and
SQCA [3–6]. Metaphase comparative genomic hybridization
(CGH) studies detected genomewide copy number changes in
lung cancers [7–10]. CGH analysis of the microarray bacterial
artificial chromosomal (BAC) clones that cover a limited frac-
tion of the human genome was also used to analyze NSCLCs
and showed a clear pattern of genomic changes for SQCAs
[11]. However, the low resolution of all the techniques makes it
difficult to identify the causal genes whose structural alteration
is critical for biologic behavior.
Most recently, CGH analysis of cDNA microarrays has
provided high-resolution maps of genomic locations of single
genes because it uses cDNA and expressed sequence tag
clones as targets [12,13]. This technique has been proven to
define genomic copy number gains and losses of individual
genes in human cancer [12–14]. With sufficient genetic repre-
sentation in cDNA microarrays, CGH resolution can be sub-
stantially improved to provide important genetic information
underlying complex chromosomal rearrangements and ge-
nomic imbalances leading to tumorigenesis.
In this study, we used cDNA microarray CGH analysis to
characterize, in detail, genomic aberrations associated with
single genes in 14 primary NSCLC tumors and their paired
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normal tissues. The results demonstrate that NSCLC tumors
share common frequency distributions of recurrent genomic
gains and losses of sets of genes. Our study also defines
the genomic difference between the two most common lung
tumor subtypes, SQCA and ADCA, and provide a clear ge-
nomic profile of primary ADCA, which shows a distinct dif-
ference from paired normal lung tissues by a cluster of
genomic aberrations. Validation of some of these genomic
signatures raises the possibility of using the findings as new
biomarkers for early detection of lung cancer.
Materials and Methods
Clinical Samples
For cDNA microarray CGH and metaphase CGH analy-
sis, surgical specimens were obtained from 14 patients with
stage I NSCLC between March 1, 2002 and June 28, 2003 at
The University of Texas M. D. Anderson Cancer Center. All
patients had a smoking history ranging from 32 to 95 pack
years. Six SQCAs and eight ADCAs had been definitively
resected by either a lobectomy or a pneumonectomy. None
of the patients had received preoperative adjuvant chemo-
therapy or radiotherapy. Tissues samples had been routinely
dissected intraoperatively from the surrounding lung paren-
chyma; paired normal lung tissues had also been obtained
from the same patients at an area distant from their tumors.
Tissue acquisition was approved by the institutional review
board at our institution. Tissue sections (4 mm thick) were
stained with hematoxylin and eosin, and reviewed to confirm
the diagnosis and to verify the presence of greater than
70% tumor cells. For fluorescence in situ hybridization
(FISH) analysis, touch imprints were made from surgical
specimens obtained from 32 patients with stage I NSCLC
(16 SQCAs and 16 ADCAs, including those used for the
cDNA microarray CGH analysis) and then fixed in methanol
and acetic acid (3:1).
Cancer cell lines BT474 and H358 were purchased from
the American Tissue Culture Collection (Rockville, MD) and
maintained in RPMI medium supplemented with 10% fetal
bovine serum. Genomic DNA was extracted from cell lines,
surgical tissues, and normal human lymphocytes using a
DNA tissue kit (QIAGEN, Inc., Valencia, CA) following the
manufacturer’s instructions.
cDNA Microarray CGH
cDNA microarrays contained a total of 8000 cDNA clones
(Research Genetics; Invitrogen, Huntsville, AL). Of these
clones, 6894 represented known genes, and the remainder
corresponded to uncharacterized expressed sequence
tags. The preparation of array slides was performed essen-
tially as described previously [12,13]. Chromosomal assign-
ments of clones were determined from the July 2003 freeze
of the assembled human genome available through the
UCSC Genome Browser (http://genome.cse.ucsc.edu).
CGH experiments on cDNA microarrays were performed
as described previously [12,13]. Briefly, 20 mg of genomic
DNA from cancer cell lines, tissue specimens, and normal
human lymphocytes was digested for 14 to 18 hours with AluI
and RsaI (New England Biolaboratories, Beverly, MA) and
purified by phenol–chloroform extraction. Six micrograms of
tested DNA was labeled with Cy3 by Bioprime labeling kit
(Invitrogen, Carlsbad, CA), and normal lung tissue DNA was
labeled with Cy5-dUTP (Invitrogen). Hybridization and post-
washes were performed as described previously [12,14]. A
laser confocal scanner (Agilent Technologies, Palo Alto, CA)
was used to measure the fluorescence intensities at the
target locations using DEARRAY software. After background
subtraction, the average intensity of each clone in the test
hybridization was divided by the average intensity of the cor-
responding clone in the control hybridization. For the copy
number analysis, the ratios were normalized on the basis of
the distribution of ratios of all targets on the array based on
126 housekeeping genes, which were spotted four times in
the array. The distributions of fluorescence ratios were used
to define cutpoints for increased or decreased copy number.
Only clones that exhibited a log2 hybridization ratio of either
>1 or <1 were considered completely amplified or deleted
candidates, respectively.
Conventional CGH
Chromosomal CGH experiments were carried out as
described in our previous publications [15,16]. Briefly, ge-
nomic DNA was labeled by nick translation using a nick
translation labeling system (Vysis, Downers Grove, IL).
Tumor samples were directly labeled with SpectrumGreen
(Vysis) and hybridized with SpectrumRed-labeled reference
DNA (Vysis). Samples were counterstained with 4,6-dia-
mino-2-phenylindole (DAPI). Each CGH experiment includ-
ed at least one normal human lymphocyte DNA as a negative
control. Images were analyzed with CGH analysis software
(Applied Imaging, Clara, CA). A gain of DNA sequence copy
number was defined as a tumor-to-reference ratio >1.2 on
both standard and inverse hybridizations. A copy number
decrease was defined as a tumor-to-reference ratio of <0.8
on both hybridizations.
FISH
By searching the genome sequence database (http://
www.ncbi.nlm.nih.gov/BLAST) using the BLAST algorithm,
we identified the following BAC clones: 2320O4 for Skp2,
307C12 for Cks1, 391M1 for Gc20/Sui1, and 506M13 for
SFTPA1. These clones were used as FISH probes. BAC
DNA was prepared using the DNA Maxi Kit (QIAGEN, Inc.).
Dual-color FISH was performed as described in our previ-
ous publication [17]. Briefly, 1 mg of BAC DNA was labeled
with SpectrumGreen (Vysis). Tissue imprint slides were de-
natured in 70% formamide and 2  SSC for 5 minutes at
72jC, dehydrated in graded ethanol, and incubated with
a hybridization mixture consisting of 60% formamide,
2  SSC, CotI DNA, and 100 ng of both a Spectrum-
Green-labeled BAC DNA probe and a SpectrumOrange-
labeled corresponding chromosomal centromeric probe
(Vysis). After overnight incubation at 37jC, the slides were
washed at 45jC in 50% formamide and 2  SSC for 10 min-
utes and counterstained with antifade solution containing
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DAPI. Two hundred cells on each slide were counted using
Leica microscopes equipped with appropriate filter sets
(Leica Microsystems, Buffalo, NY). Greater or lesser copy
numbers of the tested probes compared with copy numbers
of reference indicated gain and loss of the gene, respective-
ly. The cutoff value was calculated from normal tissue
samples using the mean number (plus 3 SD) of cells having
an abnormal FISH signal pattern.
Statistical Analyses
To analyze the cDNA microarray CGH data, clustering
analysis was performed with cluster analysis software and
in the TreeView program written by Michael Eisen [18].
Before the clustering algorithm was applied, the fluores-
cence ratio for each spot was first log-transformed (log2),
and then the data for each sample were median-centered to
remove experimental biases. To distinguish differences in the
copy number of genes between SQCAs, ADCAs, and normal
tissues, we measured 7668 clones because these clones
were present in more than 12 of 14 specimens. Each clone
was assessed by computing a two-sample t statistic with
equal variances. The P value for each test was determined
using a permutation method to calculate the ability of individ-
ual clones to distinguish between the subtypes of lung
cancer. This procedure was repeated 10,000 times. P values
less than .05 were considered significant, and the clones
associated with these significant values were thought to have
the power to distinguish between any two groups of tissues.
A Wilcoxon ranks sum test was applied to compare the
number of genomic alterations detected by conventional
CGH between different histologic subtypes, and the Stu-
dent’s t test was used to evaluate the relationships between
genomic copy number changes detected by FISH in the
different histologic subtypes. Chi-square analysis was per-
formed to examine the results of correlation between cDNA
microarray CGH and FISH regarding the genomic copy num-
ber of the genes. A P value of less than .05 was considered
statistically significant.
Results
cDNA Microarray CGH Is Sensitive in Defining Genomic
Aberrations of Genes
To assess the sensitivity of the cDNA microarray in de-
tecting the genomic copy numbers, we first tested its ability to
measure single-copy chromosomal changes by cohybridiz-
ing male DNA labeled with Cy5 and female DNA labeled with
Cy3 in the cDNA microarrays. The average log2 Cy5:Cy3
hybridization ratio for X chromosome genes was 1, which
compares to an ideal log2 value of 1 for a 2:1 female-to-male
X chromosome ratio. We then tested the ability of the cDNA
microarray to detect the genomic gain of single gene by
hybridizing breast cancer cell line BT474 genomic DNA, in
which the genomic copy number of the ERBB2 gene is ap-
proximately 10. When one third the amount of this DNA was
Figure 1. The sensitivity of the cDNA microarray CGH analysis in detecting genomic copy number. Evidence of genes that increased in copy number (log2
hybridization ratio >0) appears above the x-axis, whereas evidence of those that decreased in copy number (log2 hybridization ratio >0) appears below the x-axis.
(a) Chromosome X DNA copy number profile for male DNA compared with female DNA. The average log2 Cy5:Cy3 hybridization ratio for X chromosome genes was
1, suggesting a 2:1 female-to-male X chromosome ratio. (b) Chromosome XDNA copy number profile for male DNA cohybridized with male DNA. The average log2
Cy5:Cy3 hybridization ratio for X chromosome genes was 0, suggesting no X chromosome copy number change. (c) Chromosome 17 DNA copy number profile for
one third the amount of the BT474 DNA used compared with the normal reference DNA; the log2 hybridization ratio for the ERBB2 gene was 3.2, suggesting that
the ERBB2 copy number was approximately 3 (arrow). (d) Chromosome 17 DNA copy number profile for DNA from NCI-H358 lung cancer cells cohybridized with
normal reference DNA. The average log2 hybridization ratio for TP53 genes was1.2 (arrow), suggesting the ability of the cDNAmicroarray CGH to detect the losses
of a single gene.
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Figure 2. Comparison of metaphase CGH (a and b) and cDNA microarray CGH (c and b) for determining genomic copy number changes in 14 primary NSCLC
tumors consisting of eight ADCAs and six SQCAs. Panels (a) and (b) are summaries of relative DNA sequence copy number changes detected by metaphase CGH
in ADCAs and SQCAs, respectively. The vertical lines to the right of the chromosomal ideograms indicate copy number gains; those to the left indicate losses. Panels
(c) and (d) are summaries of the cDNA microarray CGH profile of genomic imbalances for the ADCA and SQCA specimens tested, respectively, in (a) and (b).
Evidence of genes that increased in copy number (log2 hybridization ratio >0) appears to the right of the vertical line next to each chromosomal ideogram, and
evidence of genes that decreased in copy number (log2 hybridization ratio <0) appears to the left of the vertical line next to each chromosomal ideogram. The profile
for chromosome Y is not shown because of the low representation of genes from this chromosome in the microarray.
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compared with the normal reference DNA, the log2 hy-
bridization ratio for ERBB2 genes was 3.2, suggesting that
the ERBB2 copy number was approximately 3 (Figure 1).
To assess the ability of the array to detect the deletion of
a single gene, we cohybridized DNA from NCI-H358 lung
cancer cells, which have homozygous deletion of the TP53
genome, with normal reference DNA. The average log2
hybridization ratio for TP53 genes was 1.2 (Figure 1).
Our study also allowed a direct comparison of the sensi-
tivity of the cDNA array CGH with that of the metaphase
CGH because the same samples were applied to the two
methods simultaneously. As illustrated in Figure 2, all of the
Figure 2. Continued.
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Table 1. Genes with Genomic Amplification or Deletion in Both ADCAs and SQCAs.
Gene Name Gene Description Chromosomal Location Prevalence* Reference
Genes with amplified genomic copy number
RPL37 Ribosomal protein L37 5p13 12 [19]
LAPTM4B Lysosome-associated protein transmembrane 4b 8q22.1 12
ENO1 Enolase 1 (a) 1p36.3 12 [20]
YWHAZ Tyrosine 3-monooxygenase 8q23.1 12
COL1A2 Collagen, type I, a2 7q22.1 11 [21]
RPL30 Ribosomal protein L30 8q22 11
RPS2 Ribosomal protein S2 16p13.3 11
RPS4X Ribosomal protein S4 Xq13.1 10
GNB2L1 Guanine nucleotide binding protein, b polypeptide 2-like 1 5q35.3 10
SYN1 Synapsin I Xp11.23 10
SSR4 Signal sequence receptor, y Xq28 10
JTB Jumping translocation breakpoint 1q21 10
RPS21 Ribosomal protein S21 20q13.3 9
MIF Macrophage migration-inhibitory factor 22q11.23 9 [22–27]
BASP1 Brain-abundant, membrane-attached signal protein 1 5p15.1 9
RPS10 Ribosomal protein S10 6p21.31 9
EIF3S9 Eukaryotic translation initiation factor 3, subunit 9 7p22.3 8 [28]
SNRPE Small nuclear ribonucleoprotein polypeptide E 1q32 8
RPL38 Ribosomal protein L38 17q23 8
FGF4 Fibroblast growth factor 4 11q13.3 8 [29]
IGKC Immunoglobulin n constant 2p12 7
PLP2 Proteolipid protein 2 Xp11.23 7
CRABP2 Cellular retinoic acid binding protein 2 1q21.3 6
CCT5 Chaperonin-containing TCP1, subunit 5 (epsilon) 5p15.2 6
PFN2 Profilin 2 3q25.1 6
Genes with deleted genomic copy number
ACTA2 Actin, a2, smooth muscle, aorta 10q23.3 13
GPX3 Glutathione peroxidase 3 (plasma) 5q23 13 [30]
TNA Tetranectin (plasminogen binding protein) 3p22 13 [29–31]
ANXA2 Annexin A2 15q21 13
CDKN2B Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 9p21 13 [32]
GNAI2 Guanine nucleotide binding protein (G protein) 3p21 13 [31]
DUSP1 Dual specificity phosphatase 1 5q34 12
ELAVL2 Embryonic lethal, abnormal vision, Drosophila-like 2 9p21 12
CDKN2A Cyclin-dependent kinase inhibitor 2A 9p21 12 [33,34]
SFTPC Surfactant, pulmonary-associated protein C 8p21 12 [31]
UBC Ubiquitin C 12q24.3 12
GC20/SUI1 Translation factor sui1 homolog 3p21.3 12
HYAL2 Hyaluronoglucosaminidase 2 3p21.3 12 [35]
TGFBR2 Transforming growth factor b receptor II 3p22 12 [31]
CD74 Invariant polypeptide of major histocompatibility complex, II 5q32 12 [36]
NEDD4L Neural precursor cell expressed, developmentally downregulated 4 18q21 12
FCN3 Ficolin (collagen/fibrinogen domain containing) 3 1p35 12 [31]
SFTPA Surfactant, pulmonary-associated protein A 10q22.2 12 [30,31]
COL4A2 Collagen, type IV, a2 13q34 11
MACF1 Microtubule actin cross-linking factor 1 1p32 11
SFTPB Surfactant, pulmonary-associated protein B 2p12 11 [19,30,37]
CACNA2D2 Calcium channel, voltage-dependent, a2/y subunit 2 3p21.3 11 [30,38,39]
APM2 Adipose-specific 2 10q23.2 11
SPARCL1 SPARC-like 1 4q22.1 11 [40]
ARHA Ras homolog gene family, member A 3p21.3 11 [21,36]
PSAP Prosaposin 10q21 11
RAB31 Member RAS oncogene family 18p11.3 11 [21]
B2M b2-microglobulin 15q21 11 [41]
TU3A TU3A protein 3p21.1 11
PPAP2B Phosphatidic acid phosphatase type 2B 1pter 11
TMSB4X Thymosin, b4, X-linked Xq21.3 10
DHCR24 24-Dehydrocholesterol reductase 1p33 10
ANXA11 Annexin A11 10q23 10
CDW52 CDW52 antigen (CAMPATH-1 antigen) 1p36 10
ASAH1 N-acylsphingosine amidohydrolase (acid ceramidase) 1 8p22 10
GPRK5 G protein–coupled receptor kinase 5 10q24 10
ARHGEF7 U-Guanine nucleotide exchange factor (GEF7) 13q33.3 10
GPC3 Glypican 3 Xq26.1 10 [30]
EPB41L3 Erythrocyte membrane protein band 4.1– like 3 18p11.32 10
STOM Stomatin 9q34.1 9
SLIT2 Slit homolog 2 4p15.2 9 [30,31]
VAT1 Vesicle amine transport protein 1 homolog 17q21 9
TNFAIP3 Tumor necrosis factor, a-induced protein 3 6q23 9
(continued on next page)
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imbalances identified by metaphase CGH were confirmed
by microarray CGH, whereas the copy number imbalances
at 2p, 2q, 4q, 7p, 7q, 6p, 10q, 14q, 15q, 16q, and Xq detected
by microarray CGH were not identified by metaphase CGH.
In addition, the genomic aberrations identified by meta-
phase CGH were delineated by microarray CGH to a much
smaller regions, including gains at 1q21–22, 5p13, 8q22.1–
23.1, 11q13, 19q13.1, 20q13.3, and 22q11.23, and losses
at 5q23–32, 8p21–22, 9p21, 19p13.1, and 21q22.3. There
was no statistically significant relationship between smoking
pack year and certain genomic aberrations.
Genomic Signatures of Primary NSCLCs Defined by cDNA
Microarray CGH
Consistent with the results of conventional CGH, those
of cDNA microarray CGH showed that primary SQCAs and
ADCAs share common frequency distributions of recurrent
gains and losses of genes (Figure 2). The genomic aberra-
tions involved several known oncogenes and TSGs within
1q, 3q, 5p, 8q, 16p, 17q, 19p, 19q, and 20q for gains and 1p,
3p, 5q, 8p, 9p, 11p, 11q, 13q, and 18q for losses. The total
numbers of genes with genomic aberrations are 228 in
SQCAs and 194 in ADCAs. Furthermore, using clustering
analysis of cDNA microarray CGH data, we identified 25
genes with a high number of genomic copy number changes
and another 63 genes with a high number of genomic copy
number losses in both SQCAs and ADCAs. Notably, as
Table 1 shows, molecular genetic alteration of some of
the genes has been previously described in lung tumors
[19–49].
Genomic differences associated with individual genes
between lung SQCA and ADCA subgroups can be deduced
from Figure 2, c and d. A paired t-test performed on the log-
transformed cDNA microarray CGH data identified the 57
most informative genes that allowed accurate discrimina-
tion between SQCAs and ADCAs (Figure 3). Furthermore, a
permutation t-test using 18 genes with genomic changes
was able to show a significant difference between ADCAs
and their paired normal lung tissues (Figure 4).
Validation of Genomic Signatures by FISH
To confirm whether the genomic signatures detected by
our cDNA microarray CGH analysis reflected the real fre-
quencies of the gene alterations in primary NSCLCs and
have the potential to correctly identify the two major histology
types of lung tumor, two genes (Gc20/Sui1 and SFTPA1)
with deletions in both the SQCAs and ADCAs and two genes
(Skp2 and Cks1) with genomic gains in either SQCAs or
ADCAs were selected. The copy number aberrations of the
genes were detected by FISH in a set of lung tissue speci-
mens, including those used for the cDNA microarray CGH
analysis. As shown in Table 2, there was complete concor-
dance between the cDNAmicroarray CGH and FISH results.
The genomic deletion of Gc20/Sui1 and SFTPA1 is common
for both subtypes of NSCLCs. Genomic amplification of Skp2
is specific for SQCA, whereas Cks1 amplification is more
common for ADCA (Table 2, Figure 5).
Discussion
Chromosomal aberrations reflect the selective retention of
genomic fragments housing driver genes, whose abnormal-
ity contributes to tumorigenesis. The metaphase CGH assay
has been used for the identification of novel driver genes,
and its profiles correspond well to the chromosomal location
of some known or suspected oncogenes and TSGs in lung
tumors [7–10]. However, for other frequently observed
Table 1. (Continued )
Gene Name Gene Description Chromosomal Location Prevalence* Reference
PTPRM Protein tyrosine phosphatase, receptor type, M 18p11.2 9
ADH1A Alcohol dehydrogenase 1A (class I), a polypeptide 4q21 9 [30]
C2 Complement component 2 6p21.3 9
ORM1 Orosomucoid 1 9q31 9 [42,43]
PCDHGC3 Protocadherin gamma subfamily C, 3 5q31 9
DLGAP1 Discs, large (Drosophila) homolog-associated protein 1 18p11.3 9 [44]
NSG-X Brain and nasopharyngeal carcinoma susceptibility protein 7q31 8
ID1 Inhibitor of DNA binding 1 20q11 8 [45]
CYP4B1 Cytochrome P450, family 4, subfamily B, polypeptide 1 1p34 8 [30,46]
COL6A2 Collagen, type VI, a2 21q22.3 8
HBB Hemoglobin, b 11p15.5 8
GSN Gelsolin 9q33 8 [47–49]
SCGB1A1 Secretoglobin, family 1A, member 1 (uteroglobin) 11q12.3 8
CD14 CD14 antigen 5q31.1 8
TEK TEK tyrosine kinase, endothelial 9p21 8 [21]
VAMP3 Vesicle-associated membrane protein 3 1p36.22 8
MT1G Metallothionein 1G 16q13 8
FHL1 Four and a half LIM domains 1 Xq26 7
FTH1 Ferritin, heavy polypeptide 1 11q13 7
VIPR1 Vasoactive intestinal peptide receptor 1 3p22 7
PGC Progastricsin (pepsinogen C) 6p21.3 7
SH3BP5 SH3 domain binding protein 5 (BTK-associated) 3p24.3 7
Genes with amplified genomic copy number refer to genes that are greater than four times the normal copy number.
*Number of the tumor specimens in which genomic copy number change of the genes was observed.
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Figure 3. The 57 identified most informative gene associated with a P value of less than .05 in a paired t-test comparing eight ADCAs and six SQCAs. The heat map
was made using TreeView [18]. The histologic type was given on top of the heat map.
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aberrations, no specific driver genes have yet been implicat-
ed because the method has relatively low resolution. We
demonstrated in our study that the use of cDNA microarray
CGH analysis may address this issue because cDNA micro-
arrays represent high-resolution maps (in our study, one
clone every 376 kb through the human genome), an approx-
imately 20-fold higher mapping resolution than that attained
by metaphase CGH. With the completion of the human
Figure 4. Summary of the relative DNA sequence copy number changes detected by cDNA microarray CGH analysis in eight primary ADCAs and their paired
normal lung tissues. Primary ADCAs have a clear genomic aberration profile of genes (a), which shows distinct differences from that of normal lung tissues (b). The
vertical red bars represent the separation of chromosomes. Panel (c) shows the results of a permutation t test using 18 genes that have genomic changes and shows
a significant difference between ADCAs and their paired normal lung tissues.
Table 2. Comparison of Results Obtained for Four Selected Genes From cDNA Microarray CGH and FISH Analyses*
General
Chromosomal
Location
% Positive Cases
in ADCAs by cDNA
Microarray CGH
% Positive Cases
in SQCAs by cDNA
Microarray CGH
% Positive Cases
in ADCAs by FISH
% Positive Cases
in SQCAs by FISH
cDNA Microarray
CGH Versus FISHy
Sui1 (3p21.33) 88 (7/8) 83 (5/6) 94 (15/16) 87 (14/16) <0.003
Skp2 (5p13.2) 13 (1/8) 67 (4/6) 19 (3/16) 56 (9/16) <0.01
SFTPA1 (10q22) 100 (8/8) 100 (6/6) 84 (14/16) 94 (15/16) <0.001
Cks1 (1q21) 75 (6/8) 17 (1/6) 69 (11/16) 19 (3/16) <0.01
*Specimens containing a two-fold or higher increase in the number of test Skp2 or Cks1 probe signals, compared with corresponding centromere signals, in at least
10% of the tumor cells were considered to be amplified, whereas specimens containing fewer Sui1 or SFTPA1 probe signals than the corresponding centromeric
probe signals in at least 10% of the tumor cells were considered to be deleted.
yConcordance between cDNA array CGH and FISH results was determined by chi-square analysis.
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genomic database, cDNAmicroarray CGH canmap genomic
gains and losses by their gene position rather than their chro-
mosomal band, and therefore can immediately provide a list
of candidate genes that occur within the region of interest.
The genomic copy number imbalances identified by our
cDNA microarray CGH analysis appear comparable to those
found in a recent study of lung cancer that used a BAC array
CGH technique [11]. Furthermore, because the cDNA micro-
array has a much higher mapping resolution (376 kb) than
that achieved by BAC array CGH (1.4 Mb), our study
restricted the larger fragment of genomic copy number
changes to a small focal point of copy number aberrations
of individual genes in primary lung tumors. For example, we
determined two peaks of genomic gain at 5p13 and 5p35.3 in
Figure 5. Validation of Skp2 genomic copy number changes in a SQCA specimen by metaphase CGH, cDNA microarray CGH analyses, and FISH. Metaphase
CGH (a) shows a large amplicon in chromosome 5p, which is confirmed and precisely defined by cDNA microarray CGH and includes the Skp2 oncogene (b). The
increased Skp2 copy number (c) was validated in the specimens by FISH using a Skp2 probe (green) and a centromeric probe (red), which was used as a reference.
SQCA cells contain a two- to four-fold increase in the number of Skp2 probe signals compared with the number of the reference, indicating Skp2 amplification.
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both the SQCAs and ADCAs that were not detected by the
BAC array CGH, suggesting that the use of cDNA micro-
arrays for analysis of DNA copy number variation has
marked advantages over the use of large genomic DNA
clone array-based CGH methods. Moreover, we determined
the pattern of composite genomic losses of variable regions
on several chromosomal loci in lung cancer, which was in
keeping with the complex pattern of chromosomal rearrange-
ments observed for deletions discovered by LOH [4,5];
however, our results defined a narrower region and even
identified the individual genes with genomic deletion. Thus,
our cDNA microarray CGH analysis has a higher resolution
than other methods and can be used to detect a small region
or individual genes of amplification or deletion, and, finally,
define the unique genomic signatures associated with lung
tumorigenesis.
The results of our cDNA microarray CGH analysis also
imply that primary SQCAs and ADCAs share common
recurrent DNA copy number gains and losses of certain
gene clusters, confirming previous findings that lung tumors
involve a series of clonal molecular–genetic alterations
[11,50]. We also showed that substantial genomic differ-
ences exist between SQCAs and ADCAs. For example,
when using metaphase CGH, we detected genomic gains
in both ADCAs and SQCAs; the frequency of the genomic
copy number of 3q was higher in SQCAs (100%, 6/6) than in
ADCAs (50%, 4/8) (P < .001). Correspondingly, when con-
ducting cDNA array analysis of the same specimens, gene
amplification of chromosome 3q was more frequent in
SQCAs than in ADCAs. ADCAs tended to have a more
heterogeneous gene transcript pattern and, in some cases,
to exhibit a genomic profile in 3q more similar to that of
nonneoplastic parenchymal lung tissues. The genomic copy
number difference between primary SQCAs and ADCAs
suggests that they may differ in the level of genomic insta-
bility or mechanisms by which they initiate and progress; the
genomic aberrations of specific genes in the genomic phe-
notype of each of the histologic subtypes reflect their differ-
ent genomic clonal evaluations and appear as different
diseases at the molecular level [11]. Most importantly, these
unique genomic abnormalities may be developed as predic-
tor sets of biomarkers for the early detection and classifica-
tion of lung cancers.
Previous reports using the serial analysis of gene expres-
sion, oligonucleotides, or cDNA array analysis have de-
scribed sets of genes overexpressed or downregulated in
primary SQCAs and ADCAs [21,22,30,31,36,51]. In contrast
to SQCAs, which always showed clusters as a distinct tumor
group, ADCAs tended to have a more heterogeneous gene
transcript pattern and, in some cases, to exhibit a profile
more similar to that of nonneoplastic parenchymal lung
tissues. Both of these facts make it difficult to molecularly
classify ADCA using transcript signatures [51]. In our study,
cDNA microarray CGH analysis provided a clear genomic
profile of genes in primary ADCAs that is distinctly different
from that in normal lung tissues. That genes in primary
ADCAs had a distinct genomic pattern in our study but no
clear transcriptional profile in other study is not surprising for
several reason: 1) genomic DNA is a different mixture from
the mRNA representation of cells; 2) transcription of genes
has different biologic changes and behaviors from their
genomic ancestors in lung cancer; and 3) the level of mRNA
expression does not completely reflect genomic copy num-
ber changes. In addition, the inclusion of some ADCAs with
normal lung from the previous reports may due to the
profiling of BAC bronchioloalveolar carcinomas. The com-
parison of ADCAs with normal lung at the genomic DNA level
by cDNA microarray CGH analysis should reveal the differ-
ences. Future assessment of transcript level and gene copy
number changes of the same set of lung tumors in parallel
using the same array may define whether genomic structural
abnormalities directly affect imbalances of expression in lung
tumorigenesis. However, our findings showing that primary
ADCAs have a set of genes with a unique genomic profile
may be of interests because these minimal gene sets can be
used for developing biomarkers for ADCAs. This finding is
particularly important because ADCAs have become more
prevalent than SQCAs—a trend that is occurring world-
wide—and are more difficult to diagnose than SQCAs be-
cause they always arise from the smaller airways [1].
There was no statistically significant relationship between
smoking pack year and certain genomic aberrations; one
possible reason may be the small sample size of the current
study. Currently, we are analyzing a large cohort of clinical
specimens in an ongoing study, assessing the concordance
of the genomic findings detected by cDNA microarray CGH
and correlating these data with smoking history, prognosis,
tumor progression, and treatment of the patients.
Although we used only four genes for confirmation in this
study, all four showed a strong correlation between FISH
analysis and cDNA microarray CGH data for genomic copy
number changes, indicating that the genomic signatures dis-
covered by cDNA microarray CGH might be developed as
biomarkers for early interventional strategies for lung cancer.
Furthermore, our results may suggest that the genomic
changes we observed are likely relevant to lung tumorigen-
esis. In fact, alterations of some of the genes have been
previously reported in lung cancer (Table 1). For example,
SFTPA1 is a phospholipid–protein complex that lowers the
surface tension at the air– liquid interface in the alveoli of
the lung and plays a key role in the innate host defenses
there. The transcription-level and protein-level aberration of
SFTPA1 has previously been observed in lung tumorigene-
sis [52–54]. The product of GC20/Sui1 is a general monitor
of the translational accuracy of proteins through recognition
of the protein synthesis initiation codon, and the expression
of GC20/Sui1 induced is related to cellular stress and may
represent an important adaptive response to genotoxic
agents [55]. GC20/Sui1 has been detected in normal liver
cells but not in hepatocellular carcinoma cells [56]. We found
that the GC20/Sui1 transcript was diminished in 80% of lung
cancer cell lines tested by using reverse transcription poly-
merase chain reaction (RT-PCR) (data not shown). Skp2
displays an S-phase–promoting function in the cell cycle and
is implicated in the ubiquitin-mediated degradation of several
key regulators of mammalian G1 progression, including p27,
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a dosage-dependent tumor-suppressor protein. Skp2 protein
is overexpressed in oral epithelial carcinomas, and its ex-
pression levels correlate positively with prognosis [57]. A
positive correlation of an increased relative copy number of
Skp2 with a transcriptional level was found in small cell lung
cancers cell lines [58]. Cks1 is one of the components of the
Skp1–Cullin1–F-box–Roc1 complex [59]. Inui et al. [60]
recently found a high expression of Cks1 in ADCAs and
suggested that such high expression may be involved in the
pathogenesis of the diseases. In agreement with that report,
our study’s detection of genomic gain of Cks1 by FISH and
cDNA microarray CGH analyses was common in ADCAs.
However, further characterization of the genes with a ge-
nomic aberration identified in our study is needed to evaluate
the effects of the genomic aberrations on transcriptional and
protein levels in lung cancer.
In summary, we have generated a profile of genomic copy
number aberrations in the two major histologic subtypes of
primary NSCLC tumors. Our findings may be a step toward
defining a new genomic taxonomy of such tumors and
demonstrate the potential power of genomic copy number
profiling in lung cancer diagnosis. The development and
implication of a relevant panel of probes for detecting ge-
nomic signatures might be of great value in lung cancer
diagnosis and surveillance strategies in a clinical laboratory
setting. Nevertheless, double-blind, prospective, confirmato-
ry studies by independent groups are necessary to further
validate these findings.
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